Large Cell Transformation of Mycosis Fungoides/Sezary Syndrome: Prognostic Factors and Outcomes

Rishabh Lohray(Baylor College of Medicine), Ranjit Nair(NewYork–Presbyterian Brooklyn Methodist Hospital), Chelsea C. Pinnix(The University of Texas MD Anderson Cancer Center), Jeremy Ramdial(The University of Texas MD Anderson Cancer Center), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Auris Huen(University of Pennsylvania), Luis Fayad(The University of Texas MD Anderson Cancer Center), Madeleine Duvic(Cancer Clinic), Jillian R. Gunther, Jordan Jafarnia, Samer A. Srour(The University of Texas MD Anderson Cancer Center), Julia Dai(The University of Texas MD Anderson Cancer Center), Chitra Hosing(The University of Texas MD Anderson Cancer Center), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), Sage Copling, Amy Ayers(The University of Texas MD Anderson Cancer Center), Penny Fang, Luis Malpica(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Susan Wu(The University of Texas MD Anderson Cancer Center), Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Iyanuoluwa Ogundipe(The University of Texas MD Anderson Cancer Center), Lei Feng(The University of Texas MD Anderson Cancer Center), Jie Xu(Shanghai Jiao Tong University), Carlos P Torres-Cabala(The University of Texas MD Anderson Cancer Center), Bouthaina S. Dabaja(The University of Texas MD Anderson Cancer Center), L. Jeffrey Medeiros(Delaware Division of Libraries), Mansoor Noorani(The University of Texas MD Anderson Cancer Center), Francisco Vega(The University of Texas MD Anderson Cancer Center)
European Journal of Cancer
October 1, 2025
10.1016/j.ejca.2025.115875
Cited by 0

Related Papers

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
|Blood|2007|1.4k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
|Journal of Clinical Oncology|2001|610